Trinity Biotech TRIB announces its next round of earnings this Thursday. Here is Benzinga's everything-that-matters guide for the Q2 earnings announcement.
Earnings and Revenue
Trinity Biotech earnings will be near 6 cents per share on sales of $25.5 million, according to analysts.
The Wall Street consensus estimate for earnings would represent a 11.76 percent decrease for the company. Sales would be up 0.20 percent from the same quarter last year. Trinity Biotech's reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q1 2018 | Q4 2017 | Q3 2017 | Q2 2017 |
| EPS Estimate | 0.05 | 0.07 | 0.06 | |
| EPS Actual | 0.07 | 0.04 | 0.06 | 0.068 |
Stock Performance
Over the last 52-week period, shares are down 13.44 percent. Given that these returns are generally negative, long-term shareholders are probably unhappy going into this earnings release. Analysts have adjusted their estimates lower for EPS and revenues over the past 90 days. The average rating by analysts on Trinity Biotech stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.
Conference Call
Trinity Biotech's Q2 conference call is scheduled to begin at 11:00 a.m. ET and can be accessed here: https://www.webcaster4.com/Webcast/Page/1135/26599
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
